On March 16, 2026, Vistagen Therapeutics, Inc. (the 'Company') announced the utilization of a new corporate presentation, which is attached to its Current Report on Form 8-K as Exhibit 99.1. This presentation outlines the Company's innovative approaches in neuroscience, particularly focusing on its pipeline of product candidates designed to address various mental health conditions. The presentation emphasizes the potential of pherines, a new class of rapid-onset intranasal product candidates that are not absorbed systemically and do not act directly on neurons in the brain. Vistagen's diverse pipeline includes five clinical-stage product candidates, with ongoing U.S. Phase 3 programs for the acute treatment of social anxiety disorder. The Company aims to pioneer breakthroughs in neuroscience by leveraging nose-to-brain neurocircuitry to deliver transformative treatments and improve lives. The corporate presentation also discusses the favorable safety and tolerability reported in all clinical trials to date, highlighting the potential for these products to address significant unmet medical needs in mental health. Vistagen's strategic focus on innovative treatment options positions it well within the competitive landscape of mental health therapeutics, particularly as it seeks to establish itself as a leader in the acute treatment of social anxiety disorder and other related conditions.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.